#Cytrx class actio 2017 plus#
#Cytrx class actio 2017 free#

CytRx also issued NantCell a warrant to purchase up to 3 million shares of common stock at $1.10 over the next 18 months.Īmended Long-Term Loan Facility.

#Cytrx class actio 2017 plus#

CytRx is eligible to receive up to an additional $343 million in regulatory and commercial milestones, plus increasing double-digit royalties on sales in aldoxorubicin’s lead indication of soft tissue sarcomas, and mid to high single-digit royalties for any additional indications. Under the terms of the agreement, NantCell purchased $13 million of CytRx common stock at a per share price of $1.10 representing approximately a 92% premium to the current market price. Patrick Soon-Shiong, who developed, gained regulatory approval under a 505(b)(2) pathway, and commercialized Abraxane, an albumin-mediated cytotoxic agent which currently grosses approximately $1 billion in annual sales. (a private subsidiary of NantWorks, LLC) executed a global strategic licensing agreement giving exclusive rights to NantCell to develop and commercialize aldoxorubicin for all indications. Second Quarter 2017 and Recent HighlightsĮntered an Exclusive Global Licensing Agreement and Strategic Investment with NantCell for Aldoxorubicin. Looking ahead for CytRx, we are rapidly expanding our pipeline of ultra-high potency oncology candidates at our laboratory in Freiburg, Germany, using our LADR (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CytRx’s expertise in albumin biology and linker technology for the development of a new class of potential breakthrough anti-cancer therapies.'

'We believe NantCell has the vision and expertise to maximize aldoxorubicin’s potential and bring it to the patients and physicians who need it. which charts the best path forward for aldoxorubicin, through both expansion into multiple tumor types beyond soft tissue sarcomas (STS) and innovative combinations with immuno-oncology and cell-based therapies,' said Steven A. 'We are very proud of the tireless work undertaken over the past several months to secure a high-value, strategic partnership with NantCell Inc.

#Cytrx class actio 2017 free#

Schedule your 30 min Free 1stOncology Demo!ĭiscover why more than 1,500 members use 1stOncology™ to excel in:Įarly/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing On AugCytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, reported financial results for the quarter ended June 30, 2017, and provided an overview of recent accomplishments and plans (Press release, CytRx, AUG 3, 2017, View Source ).